Introduction

Chronic Kidney Disease (CKD) has become a global public health challenge because of its higher prevalence and the concomitant increase in risk of End-Stage Renal Disease (ESRD), Cardiovascular Disease (CVD), and premature death [1-4]. Patients with early-stage CKD had no symptoms and the majority of individuals in early stage of CKD had gone undiagnosed even in developed countries [5]. In addition, previous study showed that a vast number of patients with moderate CKD die before they develop more advanced CKD [6]. The early detection of this disorder by routine screening followed by appropriate clinical intervention would offer a practical means for the prevention of condition-associated severe kidney abnormalities.

During the past decade in Taiwan, which also has undergone a dramatic socioeconomic change and a succession of unhealthy lifestyles to let an increased burden in chronic diseases? Several studies have published information on the prevalence of CKD in different Chinese populations [1,7-9]. To the best of our knowledge, however, few clinical evidence-based studies attempted to determine the prevalence and possible etiology of CKD for the female elderly agricultural and fishing population of Taiwan, which also faced to the burden of this disorder. In order to identify the prevalence of and associated risk factors for CKD, the present study was conducted to explore the potential for condition-related factors, because it was considered to know underscore important implications for the understanding of the overall pathogenesis of CKD in this sub-elderly population. As above, the purpose of this study is to investigate the context of prevalence of and cardiovascular risk factors for CKD amongst the female elderly agricultural and fishing population, as determined by the application of a healthy volunteer subjects screening program health examination in Taipei, Taiwan.

Methods

Study population
This cross-sectional study was conducted with a total of 1,606 female elderly occupational adults with agricultural and fishing professional fields voluntarily admitted to one teaching hospital in Northern Taiwan for an annual physical check-up between January, 1, 2010 and December, 31, 2010. All procedures were performed in accordance with the guidelines of our institutional ethics committee and adhered to the tenets of the Declaration of Helsinki. All patients’ information was anonymous. Informed consent was obtained from all participants before the screening.

Data collection

The medical histories and measurements of the participants were obtained by well-trained nurses. Personal and family histories of hypertension, type 2 diabetes, cardiovascular diseases, and other chronic diseases were obtained by a structured questionnaire. The participants were asked to take off the shoes and any other belongings that could possibly add extra weight when they were weighed. Heights and weights were evaluated based on Body Mass Index (BMI). The waist circumference was measured at the level of the iliac processes and the umbilicus with a soft tape measure to evaluate abdominal obesity. Blood pressures were measured twice in the sitting position with an interval of 15 min between the measurements, by means of standard sphygmomanometers of appropriate width, after a rest period for 30 min. Those taking antihypertensive therapy were considered to be hypertensive. Fasting blood samples were drawn via venipuncture from study participants by clinical nurses. Overnight-fasting serum and plasma samples (from whole blood preserved with EDTA and NaF) were kept frozen (-20°C) until ready for analysis.

Estimated glomerular filtration rate (eGFR)

The Estimated Glomerular Filtration Rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation, which was modified for data from Chinese CKD patients [7,10]. The reduced renal function was defined as an eGFR<60 mL/min/1.73m², eGFR (mL/min/1.73m²)= 175 x Calibrated Serum creatinine (mg/dL)-1.234 x age (year)-0.179 [female x 0.79].

Metabolic risk factors

Definitions of the following diseases / conditions were obesity: a BMI≥25Kg/m² and hyperuricemia (≥6mg/dL). Serum ALT level ≥40U/L was classified as elevated [11]. Metabolic syndrome was defined using the modified criteria recommended in the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines. At least 3 of the following 5 parameters should be present: abdominal obesity (waist circumference > 90 cm for males), hypertension (SBP>130 mm Hg and/or DBP>85 mm Hg) or history of antihypertensives usage, hyper-triglyceridemia (≥150 mg/dl) or presence of treatment for this disorder, low HDL-C (<40 mg/dl in males) or presence of treatment for this disorder, and high fasting plasma glucose (≥100 mg/dl) or presence of diagnosis of type 2 diabetes [12,13].

Statistical analysis

Statistical analysis was performed using SPSS for Windows, (SPSS version 18.0; Chicago, IL, USA). The two-sample independent t-test and one-way ANOVA method were adopted to assess differences in the mean value of continuous variables. The χ²-trend test was used to determine significant differences in proportions among categorical variables. Mantel-Haenszel statistics are used in the analysis of stratified categorical data. Multiple logistic regressions were also performed to investigate the independence of factors associated with the prevalence of CKD. Receiver Operating Characteristic (ROC) curves were used to explore the characteristics of a diagnostic test by graphing the false positive rate (1-specificity) on the horizontal axis and the true-positive rate (sensitivity) on the vertical axis for various cutoff values. A p-value of <0.05 was considered to represent a statistically significant difference among test populations.

Results

As figure 1 show, the overall prevalence of CKD for the female elderly study participants was 8.2% (95%CI: 6.9-9.5%). From the Cochran-Armitage trend test, the prevalence of each type of CKD showed an increase with age (p<0.0001). Subjects aged 85 years and over (25.0%, 95CI: 17.5-32.5%) had a more than 6-fold risk for CKD compared with the subjects aged 65-74 years (3.9%, 95%CI: 2.6-5.2%).

Table 1 shows the demographic characteristics of the participants who were and were not diagnosed with CKD. In addition to DBP, waist circumference, total cholesterol, serum uric acid, ALT and serum creatinine were significant difference in age subgroups. Using the two-sample independent t-test, the associated factors that were significantly related to CKD included age, metabolic components, serum uric acid, ALT, and serum creatinine.

The relationship proportion of Chinese elderly female with CKD and individual components are shown in Table 2. Hyperglycemia (p<0.001), hypertriglyceridemia (p=0.002), and low HDL-C (p=0.04) were statistically significantly associated with an increased age-specific prevalence of CKD. There was a significant relationship between the metabolic syndrome and the prevalence of CKD (p=0.003).

The effect of independent associated risk factors upon CKD was examined using the multiple logistic regression models. As is depicted in Table 3, subsequent to adjustment for confounding factors, age (OR=1.2, 95%CI: 1.09-1.15), hyperuricemia (yes vs. no, OR=7.94, 95%CI: 5.07-12.42), and hyperglycemia (yes vs. no, OR=1.67, 95%CI: 1.08-2.56).

The sensitivity and specificity of fasting blood glucose and serum uric acid concentration for the diagnosis of CKD are shown in Figure 2. For fasting blood glucose, the estimated Area under Curve (AUC)
was 0.57 (95%CI: 0.51-0.62) for diagnosis of CKD and cut-off value estimated as 94.5 mg/dl with 51.5% sensitivity and 53.5% specificity. The AUC for serum uric acid concentration in the identification of CKD was 0.79 (95%CI: 0.75-0.84) and the cut-off value, sensitivity, and specificity were 5.95 mg/dl, 76.5%, and 70.9%, respectively.

Table 1: Demographic characteristic of participants with and without chronic kidney disease (n=1606).

| Variables                  | General | 65-74 yrs | 75-84 yrs | ≥85 yrs | p-value for F-test | Yes | No | p-value for F-test |
|----------------------------|---------|-----------|-----------|---------|-------------------|-----|----|-------------------|
| Age (year)                 | 74.4±6.7| 74.2±6.4 | 74.3±6.9 | 74.5±6.9 | -                 | -   | -  | -                 |
| SBP (mm Hg)                | 139.1±37.6 | 139.2±37.4 | 143.7±39.2 | 141.3±38.4 | 0.12              | 89  | 2  | 0.001              |
| DBP (mm Hg)                | 78.4±23.6 | 79.7±24.4 | 75.8±13.5 | 75.3±12.2 | 0.007             | 79  | 2  | 0.001              |
| BMI (kg/m²)                | 25.7±4.2 | 25.9±4.1 | 25.5±4.1 | 25.3±4.8 | 0.1               | 79  | 2  | 0.001              |
| Waist circumference (cm)   | 83.4±9.7 | 82.7±9.5 | 84.5±9.5 | 83.2±11.4 | 0.003             | 84  | 2  | 0.001              |
| Fasting blood glucose (mg/dl) | 102.1±28.5 | 102.3±29.9 | 102.3±26.1 | 102.3±26.1 | 0.95              | 112| 2  | 0.001              |
| Triglycerides (mg/dl)      | 135.7±76.9 | 135.6±76.9 | 135.6±76.9 | 135.6±76.9 | 0.1              | 135| 2  | 0.001              |
| Total cholesterol (mg/dl)  | 210.0±37.5 | 212.2±37.6 | 208.4±36.7 | 201.6±36.9 | 0.005             | 204| 2  | 0.001              |
| HDL-C (mg/dl)              | 5.5±1.5 | 5.4±1.3 | 5.4±1.3 | 5.9±1.6 | <0.001             | 72  | 2  | <0.001             |
| ALT (U/L)                  | 29.9±16.5 | 31.0±17.0 | 29.1±16.2 | 26.3±14.2 | 0.003             | 27| 2  | 0.04               |
| Serum Creatinine (mg/dl)   | 8.8±0.48 | 7.6±0.45 | 8.6±0.51 | 9.7±0.49 | <0.001             | 1.7| 2  | <0.001             |

Table 2: The relationship between metabolic components and chronic kidney disease in the study participants (n=1606).

| Metabolic components | 65-74 yrs | 75-84 yrs | ≥85 yrs | Total | p-value for Mantel-Haenszel |
|----------------------|-----------|-----------|---------|-------|-----------------------------|
| Elevated blood pressure | 4.9 (3.1-6.7) | 11.6 (8.5-14.8) | 21.9 (13.6-30.2) | 9.8 (7.2-10.6) | 0.42 |
| Central obesity       | 5.4 (2.3-8.5) | 12.8 (7.6-17.6) | 18.2 (5.0-31.4) | 9.4 (6.6-12.2) | 0.53 |
| Hyperglycemia         | 9.3 (5.1-15.3) | 12.4 (6.5-18.3) | 40.0 (22.5-57.5) | 13.2 (9.6-16.8) | <0.001 |
| Hyper triglyceridemia | 6.6 (3.7-9.5) | 15.0 (9.8-20.2) | 28.6 (14.4-42.3) | 11.4 (8.6-14.2) | 0.002 |
| Low HDL-C             | 8.6 (2.0-15.2) | 16.9 (8.2-25.6) | 25.0 (14.7-56.7) | 14.3 (8.9-19.7) | 0.04 |

Metabolic syndrome

No 2.7 (1.5-3.9) | 10.7 (3.1-7.1) | 22.7 (14.4-31.0) | 7.0 (5.6-8.4) | 0.003 |

Yes 9.1 (4.7-13.5) | 13.4 (7.3-19.5) | 32.3 (15.8-48.8) | 13.0 (9.3-16.7) | 0.003 |

Table 3: Multiple logistic regression on the risk factors associated with the chronic kidney disease among female elderly fishing and agricultural population (n=1,606).

| Variables                | CKD vs. non-CKD |
|--------------------------|------------------|
| Age (year)               | Odds Ratio 1.12  |
| Hyperuricemia (yes vs. no) | 5.94 (5.07-12.42) |
| Central obesity (yes vs. no) | 1.07 (0.62-1.62) |
| Elevated blood pressure (yes vs. no) | 1.03 (0.68-1.61) |
| Hyperglycemia (yes vs. no) | 1.67 (1.08-2.56) |
| Hyper triglyceridemia (yes vs. no) | 1.24 (0.81-1.91) |
| Lower HDL-C (yes vs. no) | 1.13 (0.65-1.98) |

Figure 2: The ROC curve of fasting plasma glucose and serum uric acid concentration as a marker of chronic kidney disease.
Discussion

Clinical-epidemiological aspects for the development of chronic kidney disease

In the present CKD screening for the female elderly, the results provide an opportunity to elucidate the associations between putative factors and the clinical diagnosis of CKD. The significant associated factors in our study are congruent with the biological plausibility that cardiovascular risk factors may affect the development or progression of CKD. From the evidenced-based medicine viewpoint, Cardiovascular Disease (CVD) accounts for premature death in about 50% of dialysis patients [2]. The strong association between mild CKD and CVD has been shown and mild to moderate CKD is strongly associated with an increase in cardiovascular mortality [2,14].

Older age represented significant risk factors related to the likelihood of a CKD after adjustment for confounding factors in this study. Previous study also indicated that the prevalence of CKD increased sharply in participants after 60 years of age [15]. Renal functions deteriorate in the aged population for various reasons. The subjects might have had a renal disease, such as nephrosclerosis or ischemic kidney disease partly explain the higher prevalence of CKD in the older population [15]. Early detection of CKD could be beneficial if accompanied by early intervention and suppress the pathways for renal injury.

Consistent with previous studies [7,16], our results show that the not only hyperuricemia is strongly associated with CKD, but also this association is independent of metabolic components. This may imply that the higher uric acid is an indicator for the deterioration of CKD. Hyperuricemia is usually caused by inadequate renal excretion of uric acid and has been found to accelerate renal disease in the remnant kidney models and to accelerate experimental cyclosporine nephropathy [16,17]. Although some studies indicated that hyperuricemia may be a direct pathogenic factor in CKD, the effect of hyperuricemia on progression of kidney disease in humans remains unclear [7,18].

Recent studies indicated that metabolic syndrome also increases susceptibility [1,2,9,12,16]. There are multiple mechanisms of CKD among metabolic components, and these are not yet well delineated [18,19]. The greater the number of metabolic components indicated the greater the prevalence and incidence of CKD [20]. However, when the modified NCEP criteria was used, the numbers of subjects classified as having metabolic syndrome increased, the magnitude of risk for CKD tended to decrease [21]. This study suggests that the prevalence of CKD among elderly females is only significantly higher in subjects with, as opposed to without, hyperglycemia, and is independent of other confounding factors. Diabetes mellitus-induced renal damage is high in Asian subjects [22]. In many parts of Asia, diabetes has emerged as the leading cause of ESRD [15,21]. In addition, several lines of evidence suggest that both hypertension and dyslipidemia may be important factors for the development and progression of CKD [23,24]. We also show a positive trend for association with CKD for elevated blood pressure, hypertriglyceridemia, and lower HDL-C with similar magnitude of adjusted risk although not statistically significant.

The importance of obesity in the development and progression of CKD has been suggested by animal studies and by the development of focal segmental glomerulosclerosis in some obese human subjects [22,24]. Epidemiologic studies also examined the association between obesity and risk of CKD and reported inconsistent results [1,25,26]. In our study, when risk factors were considered individually after adjustments for confounding factors, obesity and central obesity were not associated with increased adjusted risk of prevalence of CKD. Even in the US population, the direct role of obesity as a risk factor for new CKD might be marginal [27]. The apparent lack of effect of obesity could be ascribed to the lower number of obese subjects and the lower degree of obesity rather than the lack of effects of obesity on CKD development per se [22].

It is noticing that we used ROC curve to find the cut-off value of serum uric acid and fasting blood glucose of a diagnostic test for CKD. The cut-off value of serum uric acid was estimated 5.95 mg/dl and implied that a serum uric acid higher than 5.95 mg/dl but below the 6.0 mg/dl for hyperuricemia should be considered medium risk for CKD. In addition, potential public health action point of fasting blood glucose (94.5mg/dl) should be targeted and health interventions stepwise were proposed for female elderly population to prevent the CKD. However, further studies are needed to more accurately identify the sensitivity and specificity of clinical markers in the context of CKD diagnosis such a health screening.

Methodological consideration

A major limitation in this study was the potential self-selection bias due to the hospital-based study design, which resulted in a sample that was not representative of the general population in Taiwan. However, we believe that our findings are still useful as background data for future studies of the epidemiology of CKD based on relative larger sample sizes. Secondly, this study only included subjects who were aged ≥65 years and may have different characteristics compared with whole female population. Nevertheless, this sub-population was more susceptible to have CKD and easily to know the trend happened in Taiwan and take early prevention strategies. Finally, our measurements were conducted at only a single point in time and, therefore, may not reflect long-term exposure to important demographic or biochemical factors. The solution to such a quandary would be to conduct a number of prospective longitudinal analogous studies to see if they would complement the population-based (cross-sectional) findings of this study.

Conclusion

The prevalence of CKD is related to older age, hyperuricemia, and hyperglycemia in this study. Further studies are needed to elucidate the temporal sequence of events that typically lead to CKD among elderly population. In order to prevent the CKD, promoting this female sub-population with controlled glycemic, uric acid, and health improvement for kidney function are essential.

Acknowledgements

This study was supported by the grants from the National Science Council (NSC-95-2314-B-002-MY3) and (NSC-98-2314-B-350-002-MY3).
**Authors’ Contribution**

Yi-Chun Hu, Yu-Fen Chen, Hsi-Che Shen, and Tao-Hsin Tung carried out the study and drafted the manuscript. Ya-Ting Liang participated in the design of the study and performed the statistical analysis. Hsi-Che Shen and Tao-Hsin Tung conceived of the study, participated in its design and coordination. All authors read and approved the final manuscript.

**References**

1. Chen J, Gu D, Chen CS, Wu X, Hamm LL, Muntrer P, et al. Association between the metabolic syndrome and chronic kidney disease in Chinese adults. Nephrol Dial Transplant. 2007; 22: 1100-1106.

2. Tesaro M, Canale MP, Rodia G, Di Daniele N, Lauro D, Suteri A, et al. Metabolic syndrome, chronic kidney, and cardiovascular diseases: Role of adipokines. Cardiol Res Pract. 2011.

3. Meguid EJ, Nahas AM Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005; 365: 331-340.

4. Reynolds K, He J. Epidemiology of metabolic syndrome. Am J Med Sci. 2005; 330: 273-279.

5. Yamagata K, Ishida K, Saihenco T, Takahashi H, Ohba S, Shigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007; 71: 159-166.

6. Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489-495.

7. Chen W, Chen W, Wang H, Dong X, Liu Q, Mao H, et al. Prevalence and risk factors associated with chronic kidney disease in an adult population from southern China. Nephrol Dial Transplant. 2009; 24: 1205-1212.

8. See LC, Kuo CF, Chuang FH, Shen YM, Ko YS, Yu KH, et al. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol. 2011; 30: 323-330.

9. Sun F, Tao Q, Zhan S. Metabolic syndrome and the development of chronic kidney disease among nondiabetic Taiwanese in a retrospective cohort. 2010; 15: 84-92.

10. Lord GM, Tagore R, Cook T, Gower P, Pusey Cd. Nephropathy caused by Chinese herb in the UK. Lancet. 1999; 354: 481-482.

11. Liu CM, Tung TH, Chou P, Chen VT, Hsu CT, Chien WS, et al. Clinical correlation of gallstone disease in a Chinese population in Taiwan: Experience at Cheng Hsin General Hospital. World J Gastroenterol. 2006; 12: 1281-1286.

12. Jang SY, Kim IH, Ju EY, Ahn SJ, Kim DK, Lee Sw. Chronic kidney disease and metabolic syndrome in general Korean population: the Third Korea National Health and Nutrition Examination Survey (KNHANES III) Study. J Public Health 2010; 32: 538-546.

13. Grundy SM, Cleeman JI, Daniels SE, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005; 112: 2735-2752.

14. Vanholder R, Massy Z, Argiles A, Spassovski G, Verbeke F, Lameire N, et al. Chronic kidney diseases as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20: 1048-1056.

15. Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006; 69: 369-374.

16. See LC, Kuo CF, Chuang FH, Shen YM, Ko YS, Chen YM, et al. Hyperuricemia and metabolic syndrome: associations with chronic kidney disease. Clin Rheumatol. 2011; 30: 323-330.

17. Ciriillo P, Sato W, Reungjui S, Heinig M, Gersch M, Saulin Y, et al. Uric acid, the metabolic syndrome, and renal disease. J Am Soc Nephrol. 2006; 17: 165-168.

18. Iseki K, Oshiro S, Tozawa M, Iseki C, Ikemiya Y, takishita S. Significance of hyperuricemiaon the elderly detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001; 24: 69-73.

19. Locatelli F, Pozzoni P, del Vecchio L. Renal manifestations in the metabolic syndrome. J Am Soc Nephrol. 2006; 17: 81-85.

20. Iseki K. Metabolic syndrome and chronic kidney disease: a Japanese perspective on a worldwide problem. J Nephrol. 2008; 21: 305-312.

21. Kitiyakara C, Yamwong S, Cheepudomwit S, Domrongkitkhaiporn S, Unkarapinun N, Sirata P, et al. The metabolic syndrome and chronic kidney disease? J Am Soc Nephrol. 2006; 17: 693-700.

22. Mandavilli A, Cyranoski D. Asia’s big problem. Nat Med. 2004; 10: 325-327.

23. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1996; 352: 213-219.

24. Bagby SP. Obesity-initiated metabolic syndrome and the kidney: a recipe for chronic kidney disease? J Am Soc Nephrol. 2004; 15: 2775-2791.

25. Muntrer P, Coresh J, Smioth JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000; 57: 165-168.

26. Vanholder R, Massy Z, Argiles A, Spassovski G, Verbeke F, Lameire N, et al. Chronic kidney diseases as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005; 20: 1048-1056.

27. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the kidney: a recipe for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol. 2005; 16: 2134-2140.